BofA analyst Tazeen Ahmad upgraded BioNTech to Buy from Neutral with a $239 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BNTX:
- Canada approves Pfizer, BioNTech booster vaccine for children 5 to 12
- Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
- Pfizer, BioNTech get FDA FTD for mRNA-based combination vaccine candidate
- Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
- Pfizer, BioNTech announce EUA for bivalent COVID vaccine for children under 5